Table 4.
Grades | ||||
---|---|---|---|---|
Parameter | Origin | 1 | 2 | 3 |
Creatinine (µmol l−1) | CPI | (or # 125 µmol l−1) to 1.3 ULNR assuming an increase superior to 10% | 1.3 to 1.5 | 1.5 to 2 |
FDA | 1.5 to 1.7 ULNR | 1.8 to 2 | 2.1 to 2.5 | |
NIH | 1.1 to 1.3 | 1.4 to 1.8 | 1.9 to 3.4 | |
Potassium hypokalaemia (mEq)* | CPI | Below 0.95 LLNR and decrease exceeding minus 0.2 mEq (or 3.3 to 3.1 mEq) | No relevance | ECG signs or value < or = 3 mEq |
FDA | 3.6 to 3.5 mEq | 3.4 to 3.3 | 3.2 to 3.1 | |
NIH | 3.4 to 3 mEq | 2.9 to 2.5 | 2.4 to 2 | |
Potassium hyperkalaemia (mEq)* | CPI | >to ULNR and increase exceeding 0.4 mEq | No relevance | ECG signs or value >5.5 mEq |
FDA | 5.1 to 5.2 mEq | 5.3 to 5.4 | 5.5 to 5.6 | |
NIH | 5.6 to 6 mEq | 6.1 to 6.5 | 6.6 to 7 | |
Glucose hypoglycaemia (mmol l−1)* | CPI | < to 0.9 ULNR and decrease exceeding minus 0.5 mmol l−1 (or <3.4 mmol l−1) | No relevance | Clinical signs or value <3 mmol l−1 |
FDA | 3.8 to 3.5 (65−69 mg dl−1) | 3.4 to 3 (55–64) | 2.5 to 2.9 (45–54) | |
NIH | 3.55 to 3.05 mmol l−1 | 3 to 2.2 | 2.16 to 1.67 |
Conditions: sampling without tourniquet, sample immediately assessed by the laboratory, blood glucose and not dextrostix, plus fast control confirming the persistence of the abnormality. ULNR, Upper limit of normal range; LLNR, Lower limit of normal range; CPI, Club phase I task force;